



## Viro Sure19: SARS-CoV2

### PATIENT INFORMATION

Name	: ARPIT SHAH	Sample Type	: Nasopharyngeal & Oropharyngeal
Gender	: Male	Collection Date/ Time	: 17-August-21 14:00:00 Hrs
Age (years)	: 54	Receipt Date/ Time	: 17-August-21 19:30:00 Hrs
Sample ID	: NSECGI0423749	Report Date/ Time	: 18-August-21 11:10:00 Hrs
SRF ID	: 2749700577621	Clinician Name	:
Test Code	: ViroSure19	Clinic / Hospital Name	: S N DIAGNOSTICS
Test Method	: RT-PCR	Area	: BENGALURU

### RESULTS

Test Name	Result	N Gene	Ct Value	Internal Control
SARS-CoV2 (RT- PCR)	Negative	Not Detected	NA	Detected

**INTERPRETATION : NEGATIVE FOR SARS COV-2**

#### METHODOLOGY

Test is conducted using GSD NovaPrime® SARS-CoV-2 (COVID-19) , A Multiplex Real-Time PCR for the direct qualitative pathogen detection of the novel Coronavirus (SARS-CoV-2) in human respiratory samples. The Kit is validated for simultaneous detection of two target sequences in the N gene and of the extraction / inhibition control

Checked and Approved by:



Dr. Gaurav Raikhy  
PHD, Microbiology  
Lab Head Infectious Disease

Note: The results relate only to the specimens tested and should be correlated with clinical findings.

Interpretation guidance:-

- Testing of referred clinical specimens was considered on the basis of request / referral received from / through State Surveillance Officer (SSO) of concerned State Integrated Disease Surveillance
- Testing for SARS-CoV-2 was performed on a commercial ICMR approved RT-PCR kit/ US FDA EUA/CE IVD approved kits.
- Programme (IDSP)/ any other health care facility affirming requirements of the case definition/s.
- A single negative test result, particularly if this is from an upper respiratory tract specimen, does not exclude infection\*
- A positive test result is only tentative, and will be reconfirmed by retesting.
- Repeat sampling and testing of lower respiratory specimen is strongly recommended in severe or progressive disease. The repeat specimens may be considered after a gap of 2 – 4 days after the collection of the first specimen for additional testing if required. \*
- A positive alternate pathogen does not necessarily rule out either, as little is yet known about the role of coinfections.
- Please note that these results are not to be used for any thesis or presentations or for Publication in any Journal without the prior permission of the Director General, ICMR

\*\*\*\*\*End of Report\*\*\*\*\*

COVID-19 Response Plan

Our Laboratory is open & operational as usual

"We have implemented a business continuity plan for COVID-19 to protect our staff, clients & business. Our Laboratory is amongst the cleanest and safest work environment & under the most stringent standards. The purpose of this notification is to update and assure our partners, clinicians, hospitals, colleagues & patients, that we are committed to our Company mission, as we make our way & support our communities in the current challenges"



**Eurofins Clinical Genetics India Private Limited**

540/1, Doddanakundi Industrial Area 2, Hoodi, Whitefield, Bengaluru 560048, Karnataka, India  
Tel: +91 8030982500, Email: Clinicalgenetics@eurofins.com, CIN: U74900KA2015FTC084665

